Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study

American Journal of Hematology

Volumn 88, Issue 3, 2013, Pages 166-171

  Gonzalez, Derlis E ^a   Turkia, Hadhami Ben ^b   Lukina, Elena A ^c   Kisinovsky, Isaac ^d   Dridi, Marie Françoise Ben ^b   Elstein, Deborah ^e   Zahrieh, David ^f   Crombez, Eric ^f   Bhirangi, Kiran ^f   Barton, Norman W ^f   Zimran, Ari ^e  

^a Sanatorio Español   (Paraguay)

^b LA RABTA HOSPITAL   (Tunisia)

^c NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^d Your Health SA   (Argentina)

^e HEBREW UNIVERSITY   (Israel)

^f Shire Human Genetic Therapies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOTRIOSIDASE; DRUG ANTIBODY; GLUCOSYLCERAMIDASE; HEMOGLOBIN; IMMUNOGLOBULIN G; VELAGLUCERASE ALFA;

ADOLESCENT; ADULT; ANEMIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE PAIN; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME REPLACEMENT; FAINTNESS; FEMALE; FEVER; GAUCHER DISEASE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INFLUENZA; INJURY; LIVER WEIGHT; MALE; MULTICENTER STUDY; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SPLEEN SIZE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET COUNT; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84874302849     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23381     Document Type: Article

References (22)

1. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001. pp 3635-3668.
2. Cox TM, Schofield JP. Gaucher's disease: Clinical features and natural history. Baillieres Clin Haematol 1997;10:657-689.
3. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-39.
4. Zimran A, Elstein D, Levy-Lahad E, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;345:1479-1480.
5. Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-β-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010;20:24-32.
6. Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010;115:4651-4656.
7. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al. Transglycosidase activity of chitotriosidase: Improved enzymatic assay for the human macrophage chitinase. J Biol Chem 2003;278:40911-40916.
8. Schoonhoven A, Rudensky B, Elstein D, et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 2007;381:136-139.
9. Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 2004;103:33-39.
10. Séllos-Moura M, Barzegar S, Pan L, et al. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J Immunol Methods 2011;373:45-53.
11. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115.
12. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979;6:65-70.
13. Bussink AP, van Eijk M, Renkema GH, et al. The biology of the Gaucher cell: The cradle of human chitinases. Int Rev Cytol 2006;252:71-128.
14. de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: A 2-center retrospective analysis. Blood 2006;108:830-835.
15. Ludwig J. Current methods of autopsy practice. Philadelphia: W. B. Saunders; 1979. pp 724.
16. ® human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2007;39:115-118.
17. Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007;90:157-163.
18. Chamoles NA, Blanco M, Gaggioli D, et al. Gaucher and Niemann-Pick diseases-enzymatic diagnosis in dried blood spots on filter paper: Retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002;317:191-197.
19. Dean CJ, Bockmann MR, Hopwood JJ, et al. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin Chem 2006;52:643-649.
20. Labrousse P, Chien YH, Pomponio RJ, et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 2010;99:379-383.
21. De Schoenmakere G, Poppe B, Wuyts B, et al. Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrol Dial Transplant 2008;23:4044-4048.
22. Elstein D, Cohn GM, Wang N, et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 2011;46:119-123.